Diagnostic healthcare services provider in India. Market cap ₹32,117 Cr at ₹1,916.3/share. Recent quarters show revenue ₹764–798 Cr, net profit ₹166–171 Cr—strong operational performance in core business.
PE 59.27 prices high growth; verify which drivers (volume, margin, mix) justify or if correction risk exists.
Operating margins swing 26.58%–31.2% across quarters; verify cause and if 28.32% average holds.
Public float 7.47% limits liquidity; verify trading depth and price discovery adequacy.
Healthcare diagnostics face regulatory pricing and quality scrutiny; verify compliance cost and margin impact.
Generated analysis · source review pending
Revenue growth: Jun 2026 ₹764–798 Cr vs Sep 2025 ₹700–731 Cr; verify YoY rate and trajectory.
Net profit surge ₹166–171 Cr (latest) from ₹91–92 Cr (Dec 2025); verify if volume, mix or margin-driven.
Operating margin 28.32% provides profit leverage if volumes scale; verify cost structure and pricing hold.
Zero debt (D/E 0) funds capex and M&A; verify management capital plans and deployment.
Generated analysis · source review pending
2,528 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Consolidated figures
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross margin % | 78.2% | 77.5% | 74.9% | 75.9% | 77.8% | 79.7% | 80.4% | 80.7% |
| EBITDA margin % | 24.4% | 25.8% | 27.6% | 26.9% | 24.3% | 27.4% | 28.3% | 28.3% |
| EBIT margin % | 21.2% | 20.4% | 22.7% | 21.7% | 16.8% | 20.9% | 22.5% | 22.5% |
| PAT margin % | 16.7% | 17.1% | 18.8% | 16.8% | 12% | 16.3% | 20% | 18.5% |
| Working capital | ||||||||
| Receivable days | 16 | 14 | 15 | 15 | 13 | 13 | 13 | 15 |
| Inventory days | 40 | 70 | 39 | 38 | 28 | 30 | 27 | 30 |
| Payable days | 111 | 144 | 132 | 107 | 127 | 151 | 151 | 123 |
| NWC days | -55 | -60 | -78 | -54 | -87 | -108 | -110 | -79 |
| Leverage | ||||||||
| Current ratio | 5.88 | 3.93 | 4.18 | 1.75 | 2.07 | 2.42 | 3.39 | 3.48 |
| Debt to EBITDA | — | 0 | 0 | 0.62 | 0.48 | 0.14 | 0 | 0 |
| Debt to equity | — | 0 | 0 | 0.23 | 0.14 | 0.05 | 0 | 0 |
| Interest coverage | 376.8 | 21.3 | 25.7 | 16.7 | 10.2 | 18.2 | 29 | 31.7 |
| Asset turnover | 1.1 | 0.97 | 0.95 | 0.89 | 0.85 | 0.91 | 0.91 | 0.88 |
| Return ratios | ||||||||
| Return on assets % | 18.4% | 16.6% | 17.8% | 14.9% | 10.1% | 14.8% | 18.1% | 16.2% |
| Return on capital employed % | 34.4% | 31% | 32.4% | 31.2% | 20.2% | 27.4% | 30.1% | 28.8% |
| Return on equity % | 21.2% | 22% | 23.8% | 23.2% | 14.5% | 19.6% | 22.7% | 20.3% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.61% | 54.6% | 54.6% | 54.6% | 53.92% | 53.91% | 53.91% | 53.79% | 53.21% | 53.21% | 53.21% | 53.19% | |
| 24.36% | 25.35% | 26.15% | 25.42% | 26.82% | 26.82% | 23.91% | 21.68% | 21.86% | 20.29% | 17.18% | 17.36% | |
| 9.14% | 9.56% | 9.69% | 12.71% | 12.89% | 13.17% | 16.08% | 17.91% | 18.22% | 19.21% | 21.38% | 21.59% | |
| 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.27% | 0.01% | 0.01% | 0.01% | |
| 11.48% | 10.12% | 9.24% | 6.97% | 6.04% | 5.82% | 5.84% | 6.23% | 6.07% | 6.93% | 7.87% | 7.47% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 1,12,703 | 1,16,167 | 1,14,527 | 1,11,037 |
Promoter holding down 1.42 percentage points since Sep 2023.
| Person | Deal | Shares | Value | Holding | Filed |
|---|---|---|---|---|---|
| Shankha BanerjeeKey Managerial Personnel | SellESOP | 5,750 | ₹57,500 | 0.37% → 0.36% | 6 Nov 20257(2) |
| MRINAL KAPOOREmployees/Designated Employees | SellESOP | 450 | ₹3.29 L |
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 20 Oct 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | NSE | Sell | 33,414 | ₹3,160.00 | ₹10.56 Cr |
| 20 Oct 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | NSE | Buy | 33,414 | ₹3,160.00 | ₹10.56 Cr |
| 6 Jan 2025 | MULTI-MANAGER ICVC | Bulk | NSE | Sell | 4,34,943 | ₹2,997.11 | ₹130.36 Cr |
| 25 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | BSE | Sell | 69,319 | ₹2,550.90 | ₹17.68 Cr |
| 25 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | BSE | Buy | 69,319 | ₹2,550.90 | ₹17.68 Cr |
| 25 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | BSE | Buy | 12,949 | ₹2,550.90 | ₹3.30 Cr |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | BSE | Sell | 12,949 | ₹2,550.90 | ₹3.30 Cr |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | BSE | Buy | 69,250 | ₹2,377.50 | ₹16.46 Cr |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | BSE | Sell | 69,250 | ₹2,377.50 | ₹16.46 Cr |
| 17 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | BSE | Buy | 12,934 | ₹2,377.50 | ₹3.08 Cr |
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
| 30 Sept 20257(2) |
| PUNIT SHARMAEmployees/Designated Employees | SellESOP | 1,350 | ₹32.01 L | 0.37% → 0.37% | 24 Sept 20257(2) |
| Sanjay SinghEmployees/Designated Employees | BuyESOP | 150 | ₹2.9 L | 0.00% → 0.00% | 19 Sept 20257(2) |
| Abha ChaudharyEmployees/Designated Employees | SellMarket Sale | 400 | ₹12.92 L | 0.00% → 0.00% | 18 Sept 20257(2) |
| Dr. Lal PathLabs Employees Welfare TrustOther | BuyESOP | 400 | ₹8.7 L | 0.00% → 0.00% | 16 Sept 20257(2) |
| Sanjay KulshreshthaEmployees/Designated Employees | BuyESOP | 150 | ₹2.9 L | 0.00% → 0.00% | 10 Sept 20257(2) |
| (Hony) Brig. Dr. Arvind LalPromoters | SellMarket Sale | 3,40,000 | ₹111.39 cr | 30.56% → 30.16% | 8 Sept 20257(2) |
| Dr. Lal PathLabs Employees Welfare TrustOther | BuyESOP | 400 | ₹5.8 L | 0.00% → 0.00% | 5 Sept 20257(2) |
| Shankha BanerjeeKey Managerial Personnel | SellMarket Sale | 5,000 | ₹1.63 cr | 0.03% → 0.03% | 3 Sept 20257(2) |
| (Hony) Brig. Dr. Arvind LalPromoters | SellMarket Sale | 60,000 | ₹19.98 cr | 30.64% → 30.56% | 2 Sept 20257(2) |
| ARUN BANERJEEEmployees/Designated Employees | SellMarket Sale | 300 | ₹10.31 L | 0.00% → 0.00% | 1 Sept 20257(2) |
| AMIT AGGARWALEmployees/Designated Employees | SellMarket Sale | 150 | ₹5.1 L | 0.00% → 0.00% | 29 Aug 20257(2) |
| ARUN BANERJEEEmployees/Designated Employees | SellMarket Sale | 80,000 | ₹26.78 cr | 30.73% → 30.64% | 28 Aug 20257(2) |
| PUNIT SHARMAEmployees/Designated Employees | SellMarket Sale | 740 | ₹25.06 L | 0.00% → 0.00% | 25 Aug 20257(2) |
| ARUN BANERJEEEmployees/Designated Employees | SellESOP | 1,750 | ₹19.38 L | 0.38% → 0.38% | 22 Aug 20257(2) |
| NARESH GARKOTIEmployees/Designated Employees | SellESOP | 2,500 | ₹37.1 L | 0.38% → 0.38% | 20 Aug 20257(2) |
| ARUN BANERJEEEmployees/Designated Employees | BuyESOP | 150 | ₹2.9 L | 0.00% → 0.00% | 13 Aug 20257(2) |
Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
60 schemes · 15 fund houses
| Shares | ||||||
|---|---|---|---|---|---|---|
| Large and Midcap Fund | SBI Mutual Fund | 13 L | 251.5 | 0.59% | 0.776% | -0 |
| SMALL CAP FUND | Nippon India Mutual Fund | 12.91 L | 249.75 | 0.3% | 0.77% | -0 |
| Multi Cap FundNEW | Nippon India Mutual Fund | 11.46 L | 221.8 | 0.39% | 0.684% | — |
| PHARMA FUND | Nippon India Mutual Fund | 10.01 L | 193.57 | 2.04% | 0.597% | -0 |
| Dividend Yield Fund | SBI Mutual Fund | 6.6 L | 127.68 | 1.49% | 0.394% | -0 |
| BALANCED ADVANTAGE FUNDNEW | Tata Mutual Fund | 6.11 L | 118.16 | 1.38% | 0.364% | — |
| Small Cap FundNEW | ICICI Prudential Mutual Fund | 4.79 L | 92.68 | 0.94% | 0.286% | — |
| Healthcare Opportunities Fund | SBI Mutual Fund | 4.4 L | 85.12 | 1.47% | 0.263% | +1.4 L |
Documents link to external sources (exchange filings, company investor pages).
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 | |
| COGS | 226 | 262 | 299 | 397 | 502 | 447 | 451 | 482 | 535 |
| Gross profit | 831 | 941 | 1,032 | 1,184 | 1,585 | 1,570 | 1,775 | 1,980 | 2,228 |
| 567 | 647 | 688 | 748 | 1,024 | 1,080 | 1,166 | 1,284 | 1,446 | |
| 264 | 294 | 344 | 436 | 561 | 490 | 609 | 696 | 783 | |
| OPM % | 25% | 24.4% | 25.8% | 27.6% | 26.9% | 24.3% | 27.4% | 28.3% | 28.3% |
| Depreciation | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 162 |
| Interest | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 23 |
| 31 | 46 | 55 | 51 | 53 | 42 | 69 | 93 | 71 | |
| Profit before tax | 261 | 301 | 311 | 394 | 475 | 344 | 506 | 625 | 669 |
| Tax | 90 | 100 | 83 | 98 | 125 | 103 | 143 | 133 | 159 |
| Tax % | 34.3% | 33.3% | 26.7% | 24.8% | 26.2% | 29.9% | 28.3% | 21.2% | 23.8% |
| 172 | 201 | 228 | 297 | 350 | 241 | 362 | 492 | 510 | |
| PAT margin % | 16.3% | 16.7% | 17.1% | 18.8% | 16.8% | 12% | 16.3% | 20% | 18.5% |
| EPS (₹) | 20.9 | 24.2 | 27.4 | 35.3 | 41.7 | 28.8 | 43.1 | 58.5 | 30.2 |
| EPS adjusted (₹) | 10.3 | 12 | 13.6 | 17.5 | 20.7 | 14.3 | 21.4 | 29.1 | 30.1 |
| 21.6% | 24.8% | 43.8% | 56.6% | 28.8% | 41.6% | 55.7% | 41% | 67.8% | |
| Annual report | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 | 168 |
| Reserves | 705 | 862 | 949 | 1,162 | 1,425 | 1,583 | 1,766 | 2,089 | 2,341 |
| Minority interest | 4 | 5 | 21 | 31 | 35 | 33 | 36 | 34 | 33 |
| — | — | 0 | 0 | 346 | 237 | 83 | 0 | 0 | |
| 124 | 140 | 320 | 385 | 464 | 449 | 487 | 510 | 605 | |
| Total equity & liabilities | 916 | 1,091 | 1,374 | 1,661 | 2,353 | 2,386 | 2,456 | 2,717 | 3,146 |
| 208 | 209 | 279 | 447 | 1,375 | 1,305 | 1,194 | 1,135 | 1,224 | |
| CWIP | 10 | 3 | 10 | 6 | 14 | 3 | 4 | 4 | 6 |
| Investments | 145 | 185 | 164 | 59 | 65 | 150 | 148 | 360 | 455 |
| 554 | 694 | 921 | 1,149 | 898 | 928 | 1,111 | 1,218 | 1,462 | |
| Total assets | 916 | 1,091 | 1,374 | 1,661 | 2,353 | 2,386 | 2,456 | 2,717 | 3,146 |
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 | 636 | |
| -172 | -100 | -26 | -212 | -449 | -287 | -24 | -303 | -422 | |
| 13 | -55 | -190 | -139 | 136 | -283 | -414 | -334 | -264 | |
| Net cash flow | 37 | 64 | 67 | 48 | 134 | -115 | 97 | -68 | -50 |
| Free cash flow | 135 | 184 | 237 | 363 | 353 | 420 | 484 | 525 | 469 |
| CFO / Operating profit % | 74.7% | 74.4% | 82.6% | 91.3% | 79.7% | 93.1% | 87.9% | 81.8% | 81.2% |